Abstract: A tablet, obtainable by direct comprising the active ingredient 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic (alendronic) acid or its pharmaceutically acceptable salts in an amount of 5 to 140 mg, based on the pure acid, a dry binder, a disintegrating agent, a lubricant, the tablet comprising, as the diluent, a combination of at least two diluents except lactose.
Abstract: A method for making the potassium, sodium and other hygroscopic salts of (?)-hydroxycitric acid and mixtures thereof workable by initial treatment with a desiccating agent, such as fumed silicon dioxide. These may be further rendered non-hygroscopic and non-reactive in acidic media via subsequent encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (?)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.
Abstract: Provided are a suplatast tosilate crystal showing characteristic peaks in powder X-ray diffraction diffraction angles (20±0.1°) of 5.6°, 9.0°, 11.0°, 15.3°, 16.5°, 17.2°, 17.9°, 19.2°, 19.9°, and 21.5°; and a preparation process of the crystal. Owing to merits such as fluctuation-free optically active substance ratio, low hygroscopicity and high storage stability, the suplatast tosilate crystal of the present invention can be mass-produced easily and, at the same time, is advantageous in drug preparation quality management. It is thus excellent as raw material for pharmaceuticals.
Abstract: The invention includes a nonformulated, low-dose hypocholesterolemic composition comprising soya proteins and ?-sitosterol, wherein the soya proteins and the ?-sitosterol are present in a weight ratio of about 6±1.5 of the soya proteins to about 1±0.2 of the ?-sitosterol; and wherein the composition is made up as an optimal daily dose of only the two components for adults or for children.
Abstract: The instant invention is directed toward a dermal delivery system composition comprising an aqueous base vehicle including American Emu oil, Isopropyl Palmitate (PROTACHEM IPP), PEG-8 (a polyethylene glycol available under the tradename PROTACHEM 400), methylsulfonylmethane (MSM) and SEPIGEL 305 (a combination including polyacrylamide/C13–C14 Iso-paraffin and Laureth-7), in combination with an analgesic composition, such as ibuprofen, and to processes for the manufacture and use thereof.
Abstract: A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride coated with a release-controlling film comprising a water-insoluble polymer film having no hydrophilic group. The formulation of the present invention has such a release pattern that the drug release lasts for 20 hours or more, so that can be appropriately administered for treatment. Furthermore, the formulation itself is so stable that its release pattern does not change with pH and the formulation does not suffer from deterioration, coloration and the like with the lapse of time.
Type:
Grant
Filed:
October 22, 2001
Date of Patent:
May 9, 2006
Assignee:
Ono Pharmaceutical Co., Ltd.
Inventors:
Noboru Sekiya, Yoshinori Ii, Masayuki Ishikawa, Hiroshi Azuma
Abstract: The invention is directed toward a formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles. The particle size ranges from about 0.1 mm to about 1.0 cm and is mixed in a hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 1.0 to 5.0% of the composition and a pH between 6.8–7.4 with one or more additives of a cellular material, growth factor, demineralized bone chips or mineralized bone chips.